Anteris Technologies Global Corp. (AVR) AI Stock Analysis

• Market Cap: $187.04M
• Dividend Yield: N/A
• Average Volume (3M): 178.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: -21.10%
• EPS Growth: -18.32%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.62
• Shares Outstanding: 41,197,570
• 10 Day Avg. Volume: 100,603
• 30 Day Avg. Volume: 178,125
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 41.81
• P/FCF Ratio: -1.78
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 72.54
• Enterprise Value/Gross Profit: 106.77
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: $17.50
• Price Target Upside: 195.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $4.00 ▼(-32.55% Downside)

Anteris Technologies' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and negative profitability. Technical analysis provides mixed signals, and valuation metrics are unattractive due to ongoing losses. The absence of earnings call data and corporate events leaves these areas unaddressed.

Positive Factors

Clinical Outcomes

The positive clinical outcomes for the DurAVR THV indicate strong product efficacy, which can enhance market acceptance and drive long-term revenue growth.

Regulatory Approval

FDA approval for the PARADIGM trial represents a significant milestone, potentially accelerating product development and market entry, strengthening competitive positioning.

Proprietary Technology

Anteris' focus on proprietary technologies in high-demand sectors like cardiovascular health provides a competitive edge and supports sustainable growth.

Negative Factors

Revenue Decline

The declining revenue trend poses a risk to financial stability and may hinder the company's ability to invest in growth initiatives.

Negative Profitability

Sustained negative profitability undermines financial health and limits the company's ability to reinvest in R&D and market expansion.

Cash Flow Challenges

Negative cash flow indicates liquidity issues, potentially constraining operational flexibility and investment capacity in the long term.

Anteris Technologies Global Corp. Business Overview & Revenue Model

Company Description

Anteris Technologies Global Corp. (AVR) is an innovative biotechnology company specializing in the development of advanced therapeutic solutions for various medical conditions. The company focuses on sectors such as cardiovascular health and regenerative medicine, offering products that utilize its proprietary technologies. Anteris is dedicated to improving patient outcomes through its pipeline of medical devices and therapies that enhance healing and recovery processes.

How the Company Makes Money

Anteris Technologies generates revenue primarily through the commercialization of its medical devices and therapeutic products. The company's revenue model includes direct sales of its products to healthcare providers and institutions, as well as potential licensing agreements for its proprietary technologies. Strategic partnerships with healthcare organizations and research institutions also play a significant role in its earnings, enabling Anteris to expand its market reach and drive innovation. Additionally, the company may benefit from government grants and funding aimed at supporting medical research and development, which could further contribute to its financial growth.

Anteris Technologies Global Corp. Financial Statement Overview

Summary

Anteris Technologies faces significant financial challenges with declining revenue, negative profitability, and cash flow issues. Despite a high gross profit margin and low leverage, the negative return on equity and cash flow deficits highlight the need for strategic improvements.

Income Statement

Anteris Technologies Global Corp. has experienced declining revenue with a negative growth rate of -13.71% in TTM. The company shows a negative net profit margin of -33.97% and EBIT margin of -26.25%, indicating significant losses. Despite a relatively high gross profit margin of 59.41% in TTM, the overall profitability is weak due to high operating expenses and negative net income.

Balance Sheet

The company's debt-to-equity ratio is low at 0.115, suggesting conservative leverage. However, the return on equity is negative at -252.22%, reflecting poor profitability and returns for shareholders. The equity ratio stands at 19.39%, indicating a moderate level of equity financing relative to total assets.

Cash Flow

Anteris Technologies has a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth of 4.50% in TTM. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally better than net income, but still negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.14M	2.70M	2.73M	3.20M	5.83M	5.46M
Gross Profit	1.45M	1.27M	876.80K	298.38K	1.91M	3.36M
EBITDA	-84.73M	-76.86M	-45.54M	-29.14M	-15.50M	-14.05M
Net Income	-84.32M	-76.29M	-46.02M	-30.56M	-17.17M	-11.78M
Balance Sheet
Total Assets	19.07M	80.70M	30.53M	15.99M	21.43M	9.75M
Cash, Cash Equivalents and Short-Term Investments	9.12M	70.46M	21.03M	9.29M	15.46M	3.36M
Total Debt	2.35M	1.40M	1.60M	952.79K	4.14M	2.92M
Total Liabilities	15.71M	18.02M	11.63M	6.95M	10.91M	7.90M
Stockholders Equity	3.70M	62.76M	19.30M	9.03M	10.52M	1.86M
Cash Flow
Free Cash Flow	-79.43M	-63.51M	-37.03M	-31.08M	-15.02M	-11.30M
Operating Cash Flow	-77.51M	-61.24M	-34.63M	-29.42M	-14.44M	-11.08M
Investing Cash Flow	-562.57K	-2.28M	-2.58M	-992.57K	-886.07K	5.99M
Financing Cash Flow	76.57M	112.83M	49.34M	23.27M	27.42M	1.46M

Anteris Technologies Global Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVR, the sentiment is Positive. The current price of 5.93 is above the 20-day moving average (MA) of 3.88, above the 50-day MA of 4.39, and above the 200-day MA of 4.44, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 60.00 is Neutral, neither overbought nor oversold. The STOCH value of 93.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVR.

Anteris Technologies Global Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APYX	60 Neutral	$165.35M	―	-172.18%	―	-1.32%	55.62%
RPID	56 Neutral	$178.62M	―	-68.83%	―	16.63%	10.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIK	49 Neutral	$135.99M	―	-8.73%	―	-31.29%	65.68%
AVR	44 Neutral	$187.04M	―	-2462.70%	―	-21.10%	-18.32%
INGN	43 Neutral	$189.77M	―	-13.27%	―	4.68%	55.37%
TMCI	42 Neutral	$174.59M	―	-51.63%	―	7.90%	19.92%

Anteris Technologies Global Corp. Corporate Events

Anteris Technologies Reports Positive DurAVR® THV Outcomes

On November 16, 2025, Anteris Technologies Global Corp. announced the 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli. The results, presented at the PCR London Valves conference, highlighted the valve’s favorable hemodynamic profile, with no valve-related mortality and a significant reduction in prosthesis-patient mismatch compared to existing commercial devices. These outcomes reinforce the potential of DurAVR® THV in advancing towards commercialization, with implications for improved patient outcomes in the treatment of aortic stenosis.

The most recent analyst rating on (AVR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Receives FDA Approval for PARADIGM Trial

On November 3, 2025, Anteris Technologies Global Corp. announced that it received FDA approval to commence its PARADIGM Trial, a global pivotal study of the DurAVR® Transcatheter Heart Valve (THV). This trial, which has already begun in Denmark, marks a significant milestone for the company as it aims to provide robust clinical evidence to support a future Premarket Approval (PMA) submission in the United States and CE Mark approval in Europe. The trial will enroll approximately 1000 patients across the United States, Europe, and Canada to evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs).

The most recent analyst rating on (AVR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Begins Global PARADIGM Trial Enrollment

On October 27, 2025, Anteris Technologies announced the successful enrollment and treatment of the first patients in the global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV), aimed at patients with severe calcific aortic stenosis. This trial, which is expected to expand across the United States, Europe, and Canada, will provide comparative evidence on the safety and effectiveness of the DurAVR® THV against commercially available transcatheter aortic valve replacements, potentially impacting the company’s market positioning and treatment options for aortic stenosis patients.

The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Raises $11.5M in Stock Offering

On October 23, 2025, Anteris Technologies Global Corp. entered into agreements to sell shares of its common stock and CHESS Depositary Interests (CDIs), along with accompanying five-year warrants, to certain investors. The company successfully closed the offering on October 27, 2025, issuing 2,346,936 shares and warrants, and raising approximately US$11.5 million in gross proceeds.

The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Announces Share Sale Agreement

On October 23, 2025, Anteris Technologies Global Corp. announced agreements to sell over 5 million shares and accompanying warrants, expected to generate approximately US$25 million in gross proceeds. The offerings, managed by Evolution Capital Pty Ltd, are set to close by the end of October 2025, with the funds likely enhancing Anteris’ market position and supporting its strategic initiatives in the TAVR market.

The most recent analyst rating on (AVR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Prepares for Annual Stockholder Meeting

Anteris Technologies Global Corp. will hold its first Annual Meeting of Stockholders on December 3, 2025, with the record date for stockholders set for October 30, 2025. The company has outlined procedures for stockholder proposals to be included in the proxy materials, emphasizing compliance with SEC rules and Delaware law, with a submission deadline of October 25, 2025.

The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Gains European Clearance for Heart Valve Trial

On October 15, 2025, Anteris Technologies Global Corp. announced it received its first European regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve global pivotal trial, known as the PARADIGM Trial, for patients with severe calcific aortic stenosis. This milestone positions Anteris to expand the trial across the United States, Europe, and Canada, with patient recruitment in Denmark expected to begin in the fourth quarter of 2025. The trial aims to assess the safety and effectiveness of the DurAVR® valve compared to commercial TAVR devices, potentially leading to multiple approvals and commercialization opportunities. The announcement marks a significant step in Anteris’s lifecycle, reflecting strong interest from clinicians and the potential to transform care for aortic stenosis patients.

The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Approves ASX Waiver Proposal

On September 29, 2025, Anteris Technologies Global Corp. held a special meeting where stockholders approved the ASX Waiver Proposal, allowing the company to issue new securities without stockholder approval under certain conditions. Additionally, the company provided an update on its PARADIGM Trial, with patient enrollment now expected to commence in the fourth quarter of 2025 following additional information requests from the FDA, demonstrating the company’s ongoing commitment to advancing its heart valve technology globally.

The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Adjourns Special Stockholders Meeting

On September 19, 2025, Anteris Technologies Global Corp. announced the adjournment of its Special Meeting of Stockholders due to a lack of quorum. The meeting, initially held virtually on September 18, 2025, was rescheduled to September 29, 2025, to allow more time for stockholders to vote on proposals. The company’s Board of Directors strongly recommends voting in favor of the proposals outlined in the Proxy Statement, which was filed with the SEC on August 18, 2025.

The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Postpones Special Stockholders Meeting

On September 11, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders to September 18, 2025, to allow additional time for stockholders to vote and ensure broader participation. The company’s board unanimously recommends voting in favor of the proposals in the Proxy Statement, and the record date remains unchanged. This decision reflects Anteris’ commitment to engaging its stakeholders effectively and may influence its strategic direction depending on the outcomes of the stockholder votes.

The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Postpones Special Stockholders Meeting

On September 4, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders, originally scheduled for September 4, to September 11, 2025. The delay aims to provide stockholders additional time to vote, facilitating broader participation. The company’s Board of Directors recommends voting in favor of the proposals in the Proxy Statement filed with the SEC on August 18, 2025.

The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.